Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | AOC2 | O75106 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439929 | 0.90 | PTGS2 (0.63) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL3439921 | 0.85 | PTGS2 (0.57) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL3439926 | 0.85 | PTGS2 (0.57) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL3439920 | 0.85 | PTGS2 (0.57) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL3439931 | 0.85 | PTGS2 (0.58) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL3439918 | 0.83 | PTGS2 (0.56) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL3439923 | 0.81 | ATR (0.47) | PTGS2AOC3 | |
| SCHEMBL2618376 | 0.80 | PTGS2 (0.53) | PTGS2PLK1CA1CA2CA12 | |
| SCHEMBL3439937 | 0.78 | PTGS2 (0.50) | PTGS2AOC3KCNH2CA1CA2 | |
| SCHEMBL497082 | 0.77 | PTGS2 (0.81) | PTGS2CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329728-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-c]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329728-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-c]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120095038-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095038-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095038-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | PTGS2 780/4885AOC3 2561/4885KCNH2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.